CY1108588T1 - ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ - Google Patents

ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ

Info

Publication number
CY1108588T1
CY1108588T1 CY20081101348T CY081101348T CY1108588T1 CY 1108588 T1 CY1108588 T1 CY 1108588T1 CY 20081101348 T CY20081101348 T CY 20081101348T CY 081101348 T CY081101348 T CY 081101348T CY 1108588 T1 CY1108588 T1 CY 1108588T1
Authority
CY
Cyprus
Prior art keywords
solution
hsep
treatment
ultrasonal
interfection
Prior art date
Application number
CY20081101348T
Other languages
English (en)
Inventor
Michael Weske
Lechoslaw A Turski
Hrissanthi Ikonomidou
Dieter Ziegler
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108588(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Publication of CY1108588T1 publication Critical patent/CY1108588T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η εφεύρεση σχετίζεται με μια νέα χρήση γνωστών παραγώγων βενζαζεπίνης, βενζοξαζεπίνης, βενζοθειαζεπινο-Ν-οξικού οξέος και φωσφονο-υποκατεστημένης βενζαζεπινόνης τα οποία έχουν ανασταλτική δράση της ουδέτερης ενδοπεπτιδάσης (ΝΕΡ) ή/και της ανθρώπινης διαλυτής ενδοπεπτιδάσης (hSEP). Οι ενώσεις της εφεύρεσης είναι χρήσιμες για την παρασκευή φαρμακευτικών συνθέσεων για την προφύλαξη και θεραπεία νευροεκφυλιστικών παθήσεων. Οι ενώσεις της εφεύρεσης είναι γνωστές από τα ευρωπαϊκά διπλώματα ΕΡ 0 733 642 και ΕΡ 0 916 679, και μπορούν να περιγραφούν με τον γενικό τύπο (1) στον οποίο τα σύμβολα έχουν τις σημασίες όπως δίδονται ανωτέρω στην περιγραφή.
CY20081101348T 2004-01-12 2008-11-24 ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ CY1108588T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53553804P 2004-01-12 2004-01-12
EP04100067 2004-01-12
EP05701469A EP1706121B1 (en) 2004-01-12 2005-01-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
CY1108588T1 true CY1108588T1 (el) 2014-04-09

Family

ID=34796705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101348T CY1108588T1 (el) 2004-01-12 2008-11-24 ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ

Country Status (22)

Country Link
EP (1) EP1706121B1 (el)
JP (1) JP4951350B2 (el)
KR (1) KR101219580B1 (el)
CN (1) CN101076339B (el)
AT (1) ATE406899T1 (el)
AU (1) AU2005205067B2 (el)
BR (1) BRPI0506750A (el)
CA (1) CA2551789C (el)
CY (1) CY1108588T1 (el)
DE (1) DE602005009487D1 (el)
DK (1) DK1706121T3 (el)
ES (1) ES2313279T3 (el)
HR (1) HRP20080611T3 (el)
IL (1) IL176456A (el)
NO (1) NO20063623L (el)
PL (1) PL1706121T3 (el)
PT (1) PT1706121E (el)
RU (1) RU2362563C2 (el)
SI (1) SI1706121T1 (el)
UA (1) UA82008C2 (el)
WO (1) WO2005067937A1 (el)
ZA (1) ZA200605549B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2389182A1 (en) * 2009-01-24 2011-11-30 Phytopharm PLC Treatment of neurotrophic factor mediated disorders
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
HUP0101640A3 (en) * 1998-04-23 2002-10-28 Novartis Ag Certain thoil inhibitors of endothelin-converting enzyme
US20020013307A1 (en) * 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) * 2001-03-13 2003-01-07 Micro Motion, Inc. Initialization algorithm for drive control in a coriolis flowmeter
CZ20033183A3 (cs) * 2001-05-18 2004-07-14 Solvay Pharmaceuticals Gmbh Použití sloučenin s kombinovanou inhibiční aktivitou NEP/ MP v přípravě léčiv
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
NO20063623L (no) 2006-10-12
PT1706121E (pt) 2008-12-04
HRP20080611T3 (en) 2008-12-31
RU2362563C2 (ru) 2009-07-27
DE602005009487D1 (de) 2008-10-16
AU2005205067A1 (en) 2005-07-28
UA82008C2 (uk) 2008-02-25
JP2007517834A (ja) 2007-07-05
AU2005205067B2 (en) 2009-10-22
JP4951350B2 (ja) 2012-06-13
CN101076339A (zh) 2007-11-21
EP1706121A1 (en) 2006-10-04
ATE406899T1 (de) 2008-09-15
PL1706121T3 (pl) 2009-02-27
IL176456A (en) 2010-03-28
RU2006129288A (ru) 2008-02-20
ES2313279T3 (es) 2009-03-01
IL176456A0 (en) 2006-10-05
KR20060123541A (ko) 2006-12-01
ZA200605549B (en) 2007-12-27
WO2005067937A1 (en) 2005-07-28
EP1706121B1 (en) 2008-09-03
DK1706121T3 (da) 2009-01-05
KR101219580B1 (ko) 2013-01-08
CA2551789A1 (en) 2005-07-28
CN101076339B (zh) 2011-02-09
SI1706121T1 (sl) 2009-02-28
BRPI0506750A (pt) 2007-05-22
CA2551789C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
WO2006011050A3 (en) Pyridine derivatives
MY177111A (en) Substituted amide derivatives and methods of use
MY146644A (en) Cyclohexylamin isoquinolone derivatives
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
IL164767A0 (en) 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertenision, cardiovascular or renal diseases
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
CY1108588T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
GB0514811D0 (en) Compounds
GB0407025D0 (en) Novel compounds
MX2009009409A (es) Compuestos que tienen estructura aril-sulfonamidica utiles como inhibidores de metaloproteasas.
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
TH126304A (th) สารยับยั้งของนิวตราลเอนโดเพปติเดส (Neutral Endopeptidase) (NEP) และของเอนโดเพปติเดส (Endopeptidase) ที่ละลายของคน (hSEP) สำหรับป้องกันและรักษาความผิดปกติที่เป็นการเสื่อมสลายของประสาท